Pancreatic cancer is operable in about 15% to 20% of patients at the time of diagnosis. The majority of cases are found too late, when the tumor has already spread to distant organs or grown into major blood vessels that can’t be safely reconstructed. Whether your specific case qualifies for surgery depends on the tumor’s location, its relationship to nearby arteries and veins, and whether the cancer has spread beyond the pancreas.
What Makes a Tumor Operable
Surgeons evaluate operability primarily by looking at how the tumor interacts with the major blood vessels that run through and around the pancreas. A tumor is considered clearly resectable when it doesn’t touch the two critical arteries near the pancreas (the superior mesenteric artery and the celiac artery), when the veins draining the area are open and unblocked, and when there’s no sign of cancer elsewhere in the body.
The picture gets more complicated when the tumor sits close to or touches these vessels. Doctors classify these cases into distinct categories:
- Resectable: The tumor is contained and doesn’t involve major arteries or veins. Surgery can proceed.
- Borderline resectable: The tumor touches an artery or partially blocks a vein. Surgery is possible but carries a higher risk of leaving cancer cells behind and typically requires vein reconstruction.
- Locally advanced: The tumor wraps around or encases major blood vessels. In some of these cases, chemotherapy can shrink the tumor enough to allow surgery later. In others, particularly when the tumor completely encases the superior mesenteric artery, surgery will likely never be an option.
- Metastatic: The cancer has spread to other organs, most commonly the liver or lungs. Surgery on the pancreas is not recommended at this stage.
Distant metastases, tumor invasion deep into the tissue behind the abdomen, and extensive involvement of the blood vessels feeding the intestines are all firm contraindications. If any of these are present, resection does more harm than good.
How Doctors Assess Operability
A specialized CT scan using a dedicated pancreatic protocol is the standard tool for evaluating whether a tumor can be removed. This scan maps the tumor in fine detail and shows exactly how it relates to surrounding blood vessels. MRI and PET scans play supporting roles, particularly when CT results are unclear or when doctors need to check whether cancer has spread to the liver or other sites.
Beyond imaging, a patient’s overall health matters. Someone with significant heart disease, poor lung function, or a generally weakened condition may not tolerate a major abdominal operation, even if the tumor itself looks removable on a scan.
Types of Surgery Based on Tumor Location
The specific operation depends on where in the pancreas the tumor sits. Most pancreatic cancers develop in the head of the organ, the wider end nestled into the curve of the small intestine. These require a Whipple procedure, which removes the head of the pancreas along with parts of the small intestine, bile duct, and sometimes a portion of the stomach. It’s a complex operation that offers better long-term survival but carries a higher risk of complications like delayed stomach emptying and leakage from the surgical connections.
Tumors in the body or tail of the pancreas are treated with a distal pancreatectomy, which removes the left portion of the organ along with the spleen. This is a less complex surgery with fewer complications, though these tumors tend to be found at later stages because they don’t cause symptoms like jaundice the way head tumors do. That later detection often means worse survival outcomes overall.
In some situations, the entire pancreas must be removed. A total pancreatectomy is considered when the surgeon can’t get a clean margin with a partial removal, when there are concerning changes throughout the pancreatic duct, or as an emergency salvage procedure if a prior partial surgery develops serious complications. Losing the entire pancreas means permanent diabetes and lifelong dependence on digestive enzyme supplements.
Chemotherapy Can Make Some Tumors Operable
For patients with borderline resectable tumors, chemotherapy before surgery (sometimes followed by radiation) can shrink the cancer enough to improve the chances of a complete removal. In one UK study of 62 patients with borderline tumors who received this approach, 27% were eventually able to undergo surgery. Among those who did have surgery, 73% achieved a complete removal with no cancer at the cut edges.
The chemotherapy regimen matters significantly. Patients in that study who received a combination called FOLFIRINOX had a 94% rate of complete tumor removal at the margins, compared to 42% for those on other regimens. This pre-surgical treatment has become a standard approach for borderline cases, essentially converting some previously inoperable tumors into operable ones.
Even some locally advanced tumors can become surgical candidates. Doctors now distinguish between locally advanced cases where surgery might eventually be possible after aggressive treatment and cases where the anatomy makes surgery permanently unfeasible. Complete encasement of the celiac artery, for instance, can sometimes be addressed surgically after the tumor responds to treatment. Complete encasement of the superior mesenteric artery generally cannot.
What Recovery Looks Like
Pancreatic surgery carries substantial complication rates even at experienced centers. The four most common problems are pancreatic fistula (leakage of digestive fluids from the surgical site), delayed gastric emptying where the stomach is slow to resume normal function, abdominal infections, and bleeding. Pancreatic fistulas occur in roughly 12% of cancer cases, while delayed gastric emptying affects anywhere from 8% to 45% of patients depending on how it’s defined.
Most pancreatic fistulas are low-output leaks that resolve with conservative management, meaning continued drainage without another operation. Delayed gastric emptying, while not dangerous, is a major source of discomfort. It means prolonged reliance on a tube to decompress the stomach and extends the hospital stay. Postoperative bleeding occurs in 3% to 13% of patients. These complications aren’t typically life-threatening at high-volume surgical centers, but they do mean longer hospitalizations and can delay the start of follow-up chemotherapy.
Survival After Surgery
Surgery remains the only treatment that offers a chance of curing pancreatic cancer. In a single-center study of 96 patients who underwent resection, median survival was 27 months and the five-year survival rate was 34.5%. That’s a meaningful number for a disease where the overall five-year survival across all stages sits in the single digits.
Several factors strongly predicted who would reach the five-year mark. The most significant was whether surgeons achieved a complete removal with no cancer cells at the margins. Among five-year survivors, 95% had a clean-margin resection compared to 61% of those who died within five years. The absence of cancer in nearby lymph nodes was the other major predictor: 60% of long-term survivors had cancer-free lymph nodes, versus just 18% of non-survivors. Smaller tumors, 20 millimeters or less, were also far more common in the long-term survivor group (35% versus 8%).
These numbers underscore why early detection and complete surgical removal matter so profoundly. A clean operation on a small, node-negative tumor gives the best shot at long-term survival, which is why aggressive efforts to identify operable disease early remain a priority.